NervGen Pharma Corp. NGEN
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.36% | 4.56% | 13.78% | 6.85% | 21.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.07% | 0.50% | -3.68% | 5.17% | 31.30% |
| Operating Income | -24.07% | -0.50% | 3.68% | -5.17% | -31.30% |
| Income Before Tax | 18.41% | -62.38% | -80.51% | -4.26% | -13.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.41% | -62.38% | -80.51% | -4.26% | -13.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.41% | -62.38% | -80.51% | -4.26% | -13.50% |
| EBIT | -24.07% | -0.50% | 3.68% | -5.17% | -31.30% |
| EBITDA | -24.13% | -0.52% | 3.58% | -5.31% | -31.74% |
| EPS Basic | 13.90% | -55.11% | -70.51% | 5.10% | -0.63% |
| Normalized Basic EPS | 13.86% | -55.25% | -70.57% | 5.11% | -0.59% |
| EPS Diluted | -65.89% | -74.04% | -73.07% | 2.72% | -3.03% |
| Normalized Diluted EPS | 10.22% | -55.12% | -70.57% | 5.11% | -0.59% |
| Average Basic Shares Outstanding | 12.85% | 6.36% | 7.06% | 10.00% | 13.47% |
| Average Diluted Shares Outstanding | 17.67% | 6.70% | 7.06% | 10.00% | 13.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |